Microtubules, drug resistance, and tumorigenesis

Cytoskeleton and Human Disease

Volumn 9781617797880, Issue , 2012, Pages 223-240

  McCarroll, Joshua A ^a,b   Kavallaris, Maria ^a,b  

^a University of New South Wales   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929163114     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-788-0_12     Document Type: Chapter

References (78)

1. Verhey KJ, Gaertig J (2007) The tubulin code. Cell Cycle 6(17):2152-2160
2. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10(3):194-204
3. Fojo AT, Menefee M (2005) Microtubule targeting agents: basic mechanisms of Multidrug Resistance (MDR). Semin Oncol 32(6 Suppl 7):S3-S8
4. ChienAJ, MoasserMM(2008) Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 35(2 Suppl 2):S1-14; quiz S39
5. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253-265
6. Pasquier E, Kavallaris M (2008) Microtubules: A dynamic target in cancer therapy. IUBMB Life 60(3):165-170
7. Dumontet C, Jordan MA (2010) Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 9(10):790-803
8. Downing KH (2000) Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 16:89-111
9. Nettles JH et al (2004) The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 305(5685):866-869
10. Breuninger LM et al (1995) Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55(22):5342-5347
11. Hopper-Borge E et al (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64(14):4927-4930
12. Huisman MT et al (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116(5):824-829
13. Beck WT et al (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56(13):3010-3020
14. Lhomme C et al (2008) Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26(16):2674-2682
15. Meisel C et al (2000) How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 38(9):869-876
16. Berrieman HK, Lind MJ, CawkwellL(2004)Dobeta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 5(3):158-164
17. Giannakakou P et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant betatubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272(27):17118-17125
18. Kavallaris M et al (2001) Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 61(15):5803-5809
19. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281(5381):1309-1312
20. Gajate C et al (2000) Induction of apoptosis in leukemic cells by the reversible microtubuledisrupting agent 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one: protection by Bcl-2 and Bcl-X(L) and cell cycle arrest. Cancer Res 60(10):2651-2659
21. Ibrado AM et al (1996) Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ 7(8):1087-1094
22. Tang C et al (1994) High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8(11):1960-1969
23. Deveraux QL, Reed JC (1999) IAP family proteins-suppressors of apoptosis. Genes Dev 13(3):239-252
24. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7(12):542-547
25. CheungCHet al (2009) Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 8:43
26. Ryan BM et al (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17(4):597-604
27. Schlette EJ et al (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22(9):1682-1688
28. Sui L et al (2002) Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21(2):315-320
29. Zaffaroni N et al (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59(8):1406-1412
30. ZhangMet al (2005) Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64(3):293-302
31. O'Brate A, Giannakakou P (2003) The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat 6(6):313-322
32. Wahl AF et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2(1):72-79
33. Debernardis D et al (1997) p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57(5):870-874
34. Fan S et al (1998) Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4(4):1047-1054
35. King TC et al (2000) p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 89(4):769-773
36. Malamou-Mitsi V et al (2006) Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 17(10):1504-1511
37. Luduena RF (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178;207-275
38. Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917
39. Travis WD et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244-285
40. Rosell R et al (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22(23):3548-3553
41. Seve P et al (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4(12):2001-2007
42. Koh Y et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5(3):320-325
43. Reiman T et al (2011) Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23(1):86-93
44. VilmarAC, Santoni-Rugiu E, Sorensen JB (2011) Class III {beta}-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a Randomized Trial. Clin Cancer Res 17(15):5205-5214
45. Kavallaris M et al (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282-1293
46. Kavallaris M, Burkhart CA, Horwitz SB (1999) Antisense oligonucleotides to class III betatubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80(7):1020-1025
47. Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67(19):9356-9363
48. Gan PP et al (2010) Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 9(5):1339-1348
49. McCarroll JAet al (2011) betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 70(12):4995-5003
50. Sankaranarayanan R, Ferlay J (2006)Worldwide burden of gynaecological cancer: The size of the problem. Best Pract Res Clin Obstet Gynaecol 20(2):207-225
51. Mozzetti S et al (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11(1):298-305
52. Ferrandina G et al (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12(9):2774-2779
53. Hetland TE et al (2011) Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 42(7):1019-1026
54. OhishiY et al (2007) Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 105(3):586-592
55. Cicchillitti L et al (2009) Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: The role of ERp57. J Proteome Res 8(4):1902-1912
56. Raspaglio G et al (2008) Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 409(1-2):100-108
57. Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist 12(3):271-280
58. Shalli K et al (2005) Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19(10):1299-1301
59. Tommasi S et al (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins. Int J Cancer 120(10):2078-2085
60. Stengel C et al (2010) Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102(2):316-324
61. Jemal A et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
62. PloussardGet al (2010) Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70(22):9253-9264
63. Ranganathan S et al (1996) Increase of beta(III)-and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56(11):2584-2589
64. Terry S et al (2009) Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 101(6):951-956
65. Liu B et al (2001) Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.World J Gastroenterol 7(6):855-859
66. LeeKMet al (2007) Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 51(4):539-546
67. DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114-123
68. Katsetos CD et al (2009b) Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin. J Cell Physiol 221(3):514-520
69. Katsetos CD et al (2009a) Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol 221(3):505-513
70. Katsetos CD et al (2007) Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res 32(8):1387-1398
71. Katsetos CD, Draber P, KavallarisM(2011) Targeting III-Tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 11:719-728
72. Ikota H et al (2006) Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 111(5):475-482
73. Ives NJ et al (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25(34):5426-5434
74. Zimpfer-Rechner C et al (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13(5):531-536
75. Mhaidat NM et al (2008) Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels. FEBS Lett 582(2):267-272
76. MhaidatNMet al (2007) Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res 5(10):1073-1081
77. Akasaka K et al (2009) Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol 129(6):1516-1526
78. De DonatoMet al (2011) Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol Apr 25 (Epub ahead of print)